Sanger Institute Spin-Out Microbiotica To Evaluate Bacterial Mixes
The UK Wellcome Trust Sanger Institute’s latest spin-out has received start-up funding to exploit more than six years of gut bacterial genome sequencing in order to develop novel bacteria-based therapies for a range of diseases.
You may also be interested in...
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.
Cambridge Innovation Capital, an investment firm focused on the University of Cambridge and the "Cambridge Cluster", has raised £75m for its healthcare fund in order to pursue new opportunities and expand its staff – a move highlighted as promising for the life sciences sector in the aftermath of Brexit.